The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antibiotic effectiveness: Balancing conservation against innovation
Abstract
Antibiotic effectiveness is a natural societal resource that is diminished by antibiotic use. As with other such assets, keeping it available requires both conservation and innovation. Conservation encompasses making the best use of current antibiotic effectiveness by reducing demand through vaccination, infection control, diagnostics, public education, incentives for clinicians to prescribe fewer antibiotics, and restrictions on access to newer, last-resort antibiotics. Innovation includes improving the efficacy of current drugs and replenishing effectiveness by developing new drugs. In this paper, I assess the relative benefits and costs of these two approaches to maintaining our ability to treat infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improving sanitation, expanding the use of vaccines, and strengthening hospital infection control have proven extremely effective tools in reducing the needs for antibiotic therapies.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [116]
Citations
Cites
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Self-citationGlobal Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging infectious diseases · doi:10.3201/eid1710.110655 · Cited by 2,489
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
Boeckel, T. P. V., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., & Laxminarayan, R. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70780-7 · Cited by 2,355
Self-citationNon-prescription antimicrobial use worldwide: a systematic review
Morgan, D. J., Okeke, I. N., Laxminarayan, R., Perencevich, E. N., & Weisenberg, S. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70054-8 · Cited by 947
Self-citationKyaw, M. H., Lynfield, R., Schaffner, W., Craig, A. S., Hadler, J. L., Reingold, A. L., Thomas, A. R., Harrison, L. H., Bennett, N. M., Farley, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051642 · Cited by 884
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Huttner, B. D., Goossens, H., Verheij, T. J., & Harbarth, S. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70305-6 · Cited by 591
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A. T., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 436
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Boucher, H. W., Wilcox, M. A., Talbot, G. H., Puttagunta, S., Das, A., & Dunne, M. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310480 · Cited by 433
Sabuncu, E., David, J., Bernède‐Bauduin, C., Pépin, S., Leroy, M., Boëlle, P., Watier, L., & Guillemot, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000084 · Cited by 424
Research works printed but not linked: 1
- M. Sweidan Y. Zhang K. Harvey Y. Yang X. Shen K. Yao in Proceedings of the 2nd National Workshop on Rational Use of Antibiotics in China (Beijing Children's Hospital Beijing China 2005) pp. 1–18.
Cited by
Sorted by citations
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717295115 · Cited by 3,232
Self-citationAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Self-citationEnvironmental factors influencing the development and spread of antibiotic resistance
Bengtsson-Palme, J., Kristiansson, E., & Larsson, D. G. J. (2018) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux053 · Cited by 1,167
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
Metadata
- Authors
- Laxminarayan, R.
- Affiliations
- Center for Disease Dynamics, Economics & Policy (US)
- Corresponding author
- Laxminarayan, Ramanan
- Venue
- Science
- Published
- 2014-09-12
- Volume
- 345
- Issue
- 6202
- Pages
- 1299-1301
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2004486295
- Cited by
- 170
- References
- 31
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 7 · 2023: 10 · 2022: 19 · 2021: 12 · 2020: 27 · 2019: 19 · 2018: 14 · 2017: 21 · 2016: 15 · 2015: 10 · 2014: 4
- FWCI
- 14.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- antibiotic effectiveness, antibiotic resistance, new antibiotic development, demand reduction, vaccination, infection control, antimicrobial diagnostics, prescribing incentives
- MeSH terms
- Animals, Animal Husbandry, Anti-Bacterial Agents, Communicable Disease Control, Communicable Diseases, Humans, Vaccination, Drug Resistance, Bacterial, Livestock
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
